FLUIDDA nv   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Antwerp Belgium (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2011
NCT01480661
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

roflumilast (daliresp) (2 trials)

Drugs in Phase 3 Trials (2)

fluticasone (cutivate) (1 trial)

salmeterol (serevent) (1 trial)

Drugs in Phase 2 Trials (2)

budesonide (rhinocort) (1 trial)

formoterol (foradil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Chronic Disease (Phase 4)

Lung Diseases (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5